[Percutaneous transhepatic bile duct endoprosthesis. Choice of material, technic, clinical results].
Eighty biliary endoprostheses were introduced by the transhepatic route in sixty patients with obstructive jaundice. Complication rate was 21% (no mortality). Average survival time is sixteen weeks (maximum 53 weeks). In most patients, a 12 F teflon endoprosthesis was introduced four to five days after the initial catheter drainage. Patients in poor condition had a primary implant of a 9 F endoprosthesis. A combined transhepatic/transoral implantation was carried out five times. Results have shown that implantation of a prosthesis is as effective as a surgical bypass operation for palliation of obstructive jaundice and that it is better than catheter drainage. In-vitro experiments have indicated that failure of a 12 F prosthesis due to encrustation may be expected in about 23 weeks. This is in line with the survival time of patients with carcinomas.
Lammer
J
J
D002759:Adenoma, Bile Duct / Q000601:surgery; D000328:Adult; D000368:Aged; D001650:Bile Duct Neoplasms / Q000601:surgery; D001652:Bile Ducts / Q000601:surgery*; D002779:Cholestasis / Q000601:surgery*; D005260:Female; D006801:Humans; D008297:Male; D008722:Methods; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000601:surgery; D011095:Polyethylenes; D011138:Polytetrafluoroethylene; D011140:Polyurethanes; D019736:Prostheses and Implants
D011095:Polyethylenes; D011140:Polyurethanes; D011138:Polytetrafluoroethylene
Perkutane transhepatische Gallengangs-endoprothese. Materialwahl, Technik, klinische Ergebnisse.